Wilhelm, M
Smetak, M
Reimer, P
Geissinger, E
Ruediger, T
Metzner, B
Schmitz, N
Engert, A
Schaefer-Eckart, K
Birkmann, J http://orcid.org/0000-0002-1103-9838
Article History
Received: 14 June 2016
Accepted: 20 June 2016
First Online: 29 July 2016
Competing interests
: MW, MS, EG, TR, BM and KSE have nothing to disclose, PR has honoraria (Pfizer, Celgene, Takeda, Roche) to disclose and travel expenses (Celgene, Roche, Mundipharma, Takeda, Nexion), NS has stock ownership to disclose (Celgene), honoraria (Roche, Takeda, Riemser, Gilead) and consulting (Roche, Gilead, Riemser, Takeda, cti), AE has honoraria, consulting and research funding (Takeda, Millennium) to disclose, JB has honoraria and travel expenses (both Mundipharma) to disclose.